Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | S100A9 | P06702 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.31 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16923796 | 0.83 | HTR6 (0.48) | PIK3C3HTR6CCR4HTT | |
| SCHEMBL15069582 | 0.82 | L3MBTL1 (0.41) | HTR6HTT | |
| SCHEMBL16916948 | 0.81 | PIK3C3 (0.48) | PIK3C3HTR6 | |
| SCHEMBL31073850 | 0.80 | KMT2A (0.38) | HTR6CCR4 | |
| SCHEMBL19278216 | 0.79 | ABL1 (0.36) | PIK3C3HTR6HTT | |
| SCHEMBL19100879 | 0.77 | ALDH1A1 (0.31) | — | |
| SCHEMBL16923725 | 0.77 | PIK3C3 (0.34) | PIK3C3HTR6 | |
| SCHEMBL17208676 | 0.76 | ALDH1A1 (0.31) | — | |
| SCHEMBL16475120 | 0.75 | KDM4E (0.33) | — | |
| SCHEMBL19657260 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202373-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20160333007-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20160333007-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-17 | — | — | US | disclosed |
| WO-2015108881-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333007-A1 | HETEROARYLS AND USES THEREOF | VPS35, VPS4B, VPS26B | PIK3C3 981/4885HTR6 2282/4885S100A9 4565/4885 |
| US-10202373-B2 | Heteroaryls and uses thereof | VPS35, VPS4B, VPS26B | PIK3C3 981/4885HTR6 2282/4885S100A9 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.